Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Thymus-expressed chemokine enhances Porphyromonas gingivalis LPS-induced osteoclast formation via NFATc1 activation.

Usui M, Okamatsu Y, Sato T, Hanatani T, Moritani Y, Sano K, Yamamoto M, Nakashima K.

Arch Oral Biol. 2016 Jun;66:77-85. doi: 10.1016/j.archoralbio.2016.02.011. Epub 2016 Feb 22.

PMID:
26921718
2.

Infection of RANKL-primed RAW-D macrophages with Porphyromonas gingivalis promotes osteoclastogenesis in a TNF-α-independent manner.

Kukita A, Ichigi Y, Takigawa I, Watanabe T, Kukita T, Miyamoto H.

PLoS One. 2012;7(6):e38500. doi: 10.1371/journal.pone.0038500. Epub 2012 Jun 18.

3.

Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.

Han SY, Lee KH, Kim YK.

Int J Mol Med. 2018 Jul;42(1):331-345. doi: 10.3892/ijmm.2018.3603. Epub 2018 Mar 30.

4.

CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.

Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.

Bone. 2015 Oct;79:242-51. doi: 10.1016/j.bone.2015.06.011. Epub 2015 Jun 21.

PMID:
26103094
5.

Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.

Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.

Immunol Lett. 2014 Sep;161(1):31-7. doi: 10.1016/j.imlet.2014.04.006. Epub 2014 May 2.

PMID:
24792671
6.

TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-kappaB.

Zhang P, Liu J, Xu Q, Harber G, Feng X, Michalek SM, Katz J.

J Biol Chem. 2011 Jul 8;286(27):24159-69. doi: 10.1074/jbc.M110.198085. Epub 2011 May 12.

7.

Effect of Porphyromonas gingivalis lipopolysaccharide (Pg-LPS) on the expression of EphA2 in osteoblasts and osteoclasts.

Gao A, Wang X, Yu H, Li N, Hou Y, Yu W.

In Vitro Cell Dev Biol Anim. 2016 Feb;52(2):228-34. doi: 10.1007/s11626-015-9965-0. Epub 2015 Nov 11.

PMID:
26559065
8.

Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.

Yamashita T, Uehara S, Udagawa N, Li F, Kadota S, Esumi H, Kobayashi Y, Takahashi N.

PLoS One. 2014 Jan 17;9(1):e85878. doi: 10.1371/journal.pone.0085878. eCollection 2014.

9.

Porphyromonas gingivalis Stimulates Bone Resorption by Enhancing RANKL (Receptor Activator of NF-κB Ligand) through Activation of Toll-like Receptor 2 in Osteoblasts.

Kassem A, Henning P, Lundberg P, Souza PP, Lindholm C, Lerner UH.

J Biol Chem. 2015 Aug 14;290(33):20147-58. doi: 10.1074/jbc.M115.655787. Epub 2015 Jun 17.

10.

Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.

Park CK, Kim HJ, Kwak HB, Lee TH, Bang MH, Kim CM, Lee Y, Chung DK, Baek NI, Kim J, Lee ZH, Kim HH.

Int Immunopharmacol. 2007 Dec 5;7(12):1507-16. Epub 2007 Aug 8.

PMID:
17920527
11.

Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.

Kim JY, Cheon YH, Kwak SC, Baek JM, Yoon KH, Lee MS, Oh J.

J Bone Miner Res. 2014 Jul;29(7):1541-53. doi: 10.1002/jbmr.2183.

12.
14.

Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.

Kim T, Kim K, Lee SH, So HS, Lee J, Kim N, Choi Y.

J Biol Chem. 2009 May 29;284(22):15308-16. doi: 10.1074/jbc.M807722200. Epub 2009 Mar 31.

15.

Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.

Jules J, Zhang P, Ashley JW, Wei S, Shi Z, Liu J, Michalek SM, Feng X.

J Biol Chem. 2012 May 4;287(19):15728-38. doi: 10.1074/jbc.M111.296228. Epub 2012 Mar 13.

16.

Signaling pathways in osteoblast proinflammatory responses to infection by Porphyromonas gingivalis.

Ohno T, Okahashi N, Morisaki I, Amano A.

Oral Microbiol Immunol. 2008 Apr;23(2):96-104. doi: 10.1111/j.1399-302X.2007.00393.x.

PMID:
18279176
17.

5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression.

Kang JH, Ting Z, Moon MR, Sim JS, Lee JM, Doh KE, Hong S, Cui M, Choi S, Chang HW, Park Choo HY, Yim M.

Bioorg Med Chem. 2015 Nov 1;23(21):7069-78. doi: 10.1016/j.bmc.2015.09.025. Epub 2015 Sep 15.

PMID:
26432605
18.

Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.

Wang L, Zhao R, Shi X, Wei T, Halloran BP, Clark DJ, Jacobs CR, Kingery WS.

Bone. 2009 Aug;45(2):309-20. doi: 10.1016/j.bone.2009.04.203. Epub 2009 Apr 18.

19.

A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis.

Savage JR, Pulsipher A, Rao NV, Kennedy TP, Prestwich GD, Ryan ME, Lee WY.

PLoS One. 2016 Jun 16;11(6):e0157310. doi: 10.1371/journal.pone.0157310. eCollection 2016.

20.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

Supplemental Content

Support Center